



P.O. Box 708  
Warsaw, IN 46581-0708  
574 267-6131

FEB 22 2013

### Summary of Safety and Effectiveness

<b>Sponsor:</b>	Zimmer, Inc. P.O. Box 708 Warsaw, IN 46581-0708
<b>Contact Person:</b>	Nicole J. Meredith Associate Project Manager, Regulatory Affairs Telephone: (574) 372-4517 Fax: (574) 372-4605
<b>Date:</b>	January 21, 2013
<b>Trade Name:</b>	<i>Persona™ Natural Tibia™</i> Baseplates, Size J, and Instrumentation
<b>Product Code / Device:</b>	JWH – Prosthesis, Knee, Patellofemorotibial, Semi-Constrained, Cemented, Polymer/Metal/Polymer
	OIY – Prosthesis, Knee, Patellofemorotibial, Semi-Constrained, Cemented, Polymer + Additive/Metal/Polymer + Additive
<b>Regulation Number / Description:</b>	21 CFR § 888.3560 - Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis
<b>Predicate Device:</b>	<i>Persona™ Natural Tibia™</i> Baseplate and Instrumentation, manufactured by Zimmer Inc., K113369, cleared March 27, 2012
	<i>Persona™ Natural Tibia™</i> Baseplate and Instrumentation, manufactured by Zimmer Inc., K122765, cleared November 9, 2012
<b>Device Description:</b>	The <i>Persona Natural Tibia</i> Baseplate is designed to replace the proximal portion of the tibia via cemented fixation as part of the <i>Persona Personalized Knee System</i> .
<b>Intended Use:</b>	This device is indicated for patients with severe knee pain and disability due to:

- Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.
- Collagen disorders, and/or avascular necrosis of the femoral condyle.
- Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
- Moderate valgus, varus, or flexion deformities.
- The salvage of previously failed surgical attempts or for a knee in which satisfactory stability in flexion cannot be obtained at the time of surgery.

This device is intended for cemented use only.

**Comparison to Predicate Device:**

The *Persona Natural Tibia* Baseplate and Instrumentation is similar or identical in intended use, material, sterility, and performance characteristics to the predicate devices.

**Performance Data (Nonclinical and/or Clinical):**

**Non-Clinical Performance and Conclusions:**

The following tests have been completed in support of the changes to the *Persona Natural Tibia* Baseplate: Fixation Testing, Cantilever Fatigue Testing, Bending Fatigue Testing of the keel and stem extension junction, and Cortical Impingement and Perforation Analysis using a database of computed tomography (CT) segmented tibial bones.

**Clinical Performance and Conclusions:**

Clinical data and conclusions were not needed for this device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center – WO66-G609  
Silver Spring, MD 20993-002

February 22, 2013

Zimmer, Incorporated  
% Ms. Nicole J. Meredith  
Associate Project Manager, Regulatory Affairs  
P.O. Box 708  
Warsaw, Indiana 46581-0708

Re: K130143

Trade/Device Name: Persona™ Natural Tibia™ Baseplates, Size J and  
Instrumentation

Regulation Number: 21 CFR 888.3560

Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-constrained  
cemented prosthesis

Regulatory Class: Class II

Product Code: JWH, OIY

Dated: January 21, 2013

Received: January 23, 2013

Dear Ms. Meredith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOFFICES/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

The signature is handwritten in black ink. It consists of the first name "Erin" followed by a stylized middle initial "D", and the last name "Keith". The "D" is formed by a vertical line with a diagonal stroke through it, and the "K" has a unique, angular design.

Mark N. Melkerson  
Director  
Division of Orthopedic Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

**510(k) Number (if known):** K130143

**Device Name:**

*Persona™ Natural Tibia™ Baseplates, Size J, and Instrumentation*

**Indications for Use:**

This device is indicated for patients with severe knee pain and disability due to:

- Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.
- Collagen disorders, and/or avascular necrosis of the femoral condyle.
- Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
- Moderate valgus, varus, or flexion deformities.
- The salvage of previously failed surgical attempts or for a knee in which satisfactory stability in flexion cannot be obtained at the time of surgery.

This device is intended for cemented use only.

Prescription Use X  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(Please do not write below this line – Continue on another page if needed)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Anton E. Dmitriev, PhD  2013.02.21 15:54:54  
Division of Orthopedic Devices  05'00'